Your browser doesn't support javascript.
loading
Therapeutic targets of hypercholesterolemia: HMGCR and LDLR.
Ma, Shizhan; Sun, Wenxiu; Gao, Ling; Liu, Shudong.
Afiliação
  • Ma S; Department of Endocrinology and Metabolism, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, People's Republic of China.
  • Sun W; Department of Endocrinology and Metabolism, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, People's Republic of China.
  • Gao L; Department of Pharmacy, Taishan Vocational College of Nursing, Taian 271000, People's Republic of China.
  • Liu S; Department of Endocrinology and Metabolism, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, People's Republic of China.
Diabetes Metab Syndr Obes ; 12: 1543-1553, 2019.
Article em En | MEDLINE | ID: mdl-31686875
Cholesterol homeostasis is critical and necessary for the body's functions. Hypercholesterolemia can lead to significant clinical problems, such as cardiovascular disease (CVD). 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and low-density lipoprotein cholesterol receptor (LDLR) are major points of control in cholesterol homeostasis. We summarize the regulatory mechanisms of HMGCR and LDLR, which may provide insight for new drug design and development.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diabetes Metab Syndr Obes Ano de publicação: 2019 Tipo de documento: Article País de publicação: Nova Zelândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diabetes Metab Syndr Obes Ano de publicação: 2019 Tipo de documento: Article País de publicação: Nova Zelândia